At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06419673Phase 2ActiveUpdate OverdueUpdated 25mo ago · Completion was 13mo agoInduced and Concurrent Serplulimab Plus Chemoradiotherapy Followed by Toripalimab Maintenance Therapy for Stage III-IVA Cervical Cancer: a Prospective, Multicenter, Randomized, Open Controlled Clinical Trial
In Brief
A Phase 2 clinical trial evaluating Serplulimab, Cisplatin, and 2 other interventions for Cervical Cancer. Active but no longer recruiting, targeting 240 participants across 1 site.
Signals
Detailed Summary
This study is a prospective, multicenter, randomized, open controlled clinical trial aimed at evaluating the effectiveness and safety of serplulimab plus chemoradiotherapy in FIGO 2018 stage III or IVA cervical squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma patients who have not received prior treatment.
Study Details
Timeline
Interventions
Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
IV infusion
IV infusion
Brachytherapy and External Beam Radiotherapy